Amsel Medical

Amsel Medical Signs $7.45M Phase III SBIR Contract

Antonette Ho2024-10-26T09:40:47-04:00Amsel Medical Corporation today announces that it has been awarded an $7.45 million sole source, non-dilutive, small business innovative research (SBIR) Phase III contract by the United States Air Force. This award represents a significant milestone for the company and builds on successful prior AFWERX Phase I, Phase II and TACFI SBIR contracts with the U.S. Air Force. This contract will help accelerate the commercialization of Amsel’s breakthrough, SCureTO™, precision hemorrhage control solution for combat casualty care trauma. It is...

Amsel Medical Announces Appointment of Chief Executive Officer

Antonette Ho2024-08-15T00:07:48-04:00Amsel Medical Corporation is pleased to announce the appointment of James A. Heinz, MSL as Chief Executive Officer of Amsel effective July 30, 2024. Mr. Heinz began his service in October 2023 with Amsel as a Board Advisor, later joining Amsel as its Senior Vice President for Strategic Development. Arnold Miller, M.D., Amsel Founder, President and Chief Medical Officer, remarked: ""We are fortunate to have someone of James's caliber and experience as Amsel's CEO,"" noting his more than 20 years'...

Top 15 Medical Startups 2022

Antonette Ho2022-12-04T19:58:59-05:00Amsel Medical on list. Read more >>

Amsel Medical Announces $1.5 million AFWERX TACFI Grant Award

Ziad2022-11-25T13:59:44-05:00Amsel Medical Corporation today announced receipt of award and signing of a contract for a non-dilutive AFWERX Tactical Funding Increase (TACFI) of $1.5 million augmenting its original $1M Phase II SBIR Grant. his effort is sponsored by the Air Force Research Laboratory and will enable Amsel Medical to bridge its Phase II efforts towards Phase III commercial scaling. It facilitates the delivery of strategic capabilities to the U.S. Air Force, Special Operations Command, and U.S. Department of Defense (DoD).